Skip to main content
Karo Pharma AB logo

Karo Pharma AB — Investor Relations & Filings

Ticker · KARO ISIN · SE0007464888 LEI · 213800G54Z51LOPGTA79 ST Manufacturing
Open in API
Filings indexed 653 across all filing types
Latest filing 2009-10-22 Interim / Quarterly Rep…
Country SE Sweden
Listing ST KARO

About Karo Pharma AB

https://www.karohealthcare.com/

Karo Pharma AB, operating as Karo Healthcare, is a healthcare company that develops, markets, and sells a broad portfolio of everyday healthcare products. The company's offerings are designed to prevent illness and treat common health problems, empowering consumers to manage their daily well-being. The portfolio consists of various branded medicines and consumer healthcare products distributed through pharmacies and directly to healthcare providers. With products available in over 90 countries, the company focuses on becoming a leading force in its sector by employing a consumer-centric approach, strategic innovation, and omnichannel excellence.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2009
Interim / Quarterly Report Classification · 100% confidence The document is titled 'INTERIM REPORT JANUARY–SEPTEMBER 2009' and contains comprehensive financial statements, including net sales, loss per share, cash flow, and balance sheet summaries for the specified period. It also includes detailed management commentary, project portfolio updates, and R&D progress. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. 9M 2009
2009-10-22 English
Interim / Quarterly Report 2009
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for the period January-September 2009. It contains comprehensive financial data, including income statements, cash flow, and balance sheet summaries, as well as detailed management commentary on research and development projects (Eprotirome, KB3305, ER-beta). It is not a mere announcement or certification, but the full interim financial report itself. 9M 2009
2009-10-22 Swedish
Regulatory Filings 2009
Regulatory Filings Classification · 95% confidence The document is a press release dated October 20, 2009, titled "KARO BIO UPPDATERAR SIN PROJEKTPORTFÖLJ" (Karo Bio Updates Its Project Portfolio). It details updates on specific drug development projects (ER-beta, Eprotirome, KB3305), including nomination of candidates, filing applications with the FDA, and decisions to discontinue or seek partners. This content describes operational and strategic developments, which aligns best with an announcement regarding company activities or investor relations updates, rather than a formal regulatory filing like a 10-K, an earnings release (ER), or a formal capital change (CAP). Since it is a general operational update announcement, and not a specific financial report, it fits best under the general 'Regulatory Filings' (RNS) category as a broad announcement, or potentially a general Investor Relations update, but RNS is the most appropriate fallback for non-standard, non-financial-specific announcements that are not explicitly defined elsewhere. Given the nature of the content (pipeline updates), it is a general corporate announcement.
2009-10-20 Swedish
Investor Presentation 2009
Investor Presentation Classification · 92% confidence The document is a press release dated October 20, 2009, titled "KARO BIO UPDATES ITS PROJECT PORTFOLIO." It details specific updates on drug development candidates (ER-beta, Eprotirome, KB3305), including nomination of candidates, submission of FDA applications, and discontinuation of in-house development for one project. This content focuses on the status of the company's pipeline and strategic decisions regarding its assets, which aligns best with an Investor Presentation (IP) or a general announcement. Since it is a brief press release announcing strategic operational updates rather than a full financial report (10-K, IR) or a formal regulatory filing about share transactions or dividends, it fits the profile of an Investor Presentation (IP) which often includes strategic updates, or potentially a Regulatory Filing (RNS) if it were less specific. Given the detailed project pipeline updates and strategic commentary from the CEO, 'Investor Presentation' (IP) is a strong fit, as these updates are crucial for investors. However, because it is a short press release format announcing operational news rather than a formal presentation deck, and it doesn't fit other specific categories like ER, CAP, or DIV, the most appropriate general category for strategic operational news announcements that aren't full financial reports is often RNS, or IP if the content is highly strategic. Given the focus on pipeline progress and strategic decisions, IP is slightly better than RNS, but since it's a short announcement, I will check the definitions again. It is not an Earnings Release (ER), nor a Capital Update (CAP). It is a strategic update. In the absence of a specific 'Pipeline Update' code, and noting its brevity (4183 chars) and nature as a news announcement, it could be RNS. However, the content is highly relevant to investors regarding R&D strategy. I will classify it as an Investor Presentation (IP) as it functions as a high-level strategic update for investors, even if not in slide format. If it were purely administrative, RNS would be chosen. The content is too substantive for just RNS.
2009-10-20 English
Major Shareholding Notification 2009
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding for a specific instrument (Aktier SE0000571416) by a holder (Nordnet AB (publ)) in Karo Healthcare AB. It explicitly states the 'Reason for major shareholding notification Sell' and provides 'Before the transaction' and 'After the transaction' figures, showing a reduction in holding from 5,840,229 shares to 5,687,018 shares, resulting in a new percentage of 4.9%. This structure—reporting changes in ownership that cross or move below specific thresholds (like 5%)—is characteristic of a Major Shareholding Notification. The code corresponding to this is MRQ (Major Shareholding Notification). The document length is short (3007 chars), but the content is the notification itself, not an announcement of a report.
2009-10-02 English
Major Shareholding Notification 2009
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding percentage for a specific holder (Nordnet AB (publ)) in the issuer (Karo Healthcare AB). It explicitly mentions 'Reason for major shareholding notification Buy' and provides 'Before the transaction' and 'After the transaction' figures, culminating in a new percentage (5.03%). This structure perfectly matches the definition of a Major Shareholding Notification, which corresponds to the filing code MRQ.
2009-10-01 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.